Free Trial

Atrion Q2 2023 Earnings Report

Atrion EPS Results

Actual EPS
$3.73
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrion Revenue Results

Actual Revenue
$43.84 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrion Announcement Details

Quarter
Q2 2023
Time
N/A

Atrion Earnings Headlines

Q3 2024 Nordson Corp Earnings Call
He called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.
With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.
Atrion Corp (AN2.BE)
See More Atrion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrion and other key companies, straight to your email.

About Atrion

Atrion (NASDAQ:ATRI), together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

View Atrion Profile

More Earnings Resources from MarketBeat